Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCLEROCAR anti-CD19 CAR-T trial in refractory systemic sclerosis
2024-519511-33-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Jun 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zorpocabtagene autoleucel in systemic sclerosis (SSc), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Improvement in modified Rodnan Skin Score. Planned start Jun 2026; status: authorised.
02
Drugs
zorpocabtagene autoleucel
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2024-519511-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519511-33-00.